spacer
home > ict > winter 2017 > out of control
PUBLICATIONS
International Clinical Trials

Out of Control

The first documented outbreak of the Ebola virus disease – more commonly known as Ebola – occurred in 1976 in South Sudan and the Democratic Republic of the Congo. Nearly 40 years later in 2013, the most widespread outbreak of Ebola in history started in the West African country of Guinea and quickly spread to the neighbouring countries of Liberia and Sierra Leone.

While previous outbreaks were brought under control within a matter of weeks, this one became an epidemic that raged on for over two years, resulting in more than 11,000 deaths and significant social disruption. A number of factors contributed to the failure to control this flare-up, including extreme poverty in the affected areas; a dysfunctional healthcare system in affected countries; a population with enormous distrust of government officials after years of armed conflict; several months of delay in government agency response to the outbreak; and the unprecedented spread of Ebola to densely populated cities.

Even with previous Ebola epidemics on record, there were no licensed vaccines, no treatments with proven efficacy in humans and no diagnostics that met the WHO’s target product profile for a rapid, simple Ebola virus disease test at the start of this spread. The lack of effective treatments, combined with the severity of the breakout, triggered an unprecedented global response to tackle the epidemic that provides a compelling case study for accelerated drug development models.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
goBalto’s Chief Executive Officer Sujay Jadhav has over 20 years of experience with leading Silicon Valley software providers with a life sciences focus. Most recently, he was Senior Vice President of Global Corporate Strategy and Development at Model N, and held a variety of roles in Strategy Consulting at Booz Allen Hamilton, Product Strategy at CommerceOne and General Management at Singapore Telecom. Sujay received his Bachelor’s degree from the University of South Australia and an MBA from Harvard University, US.
spacer
Sujay Jadhav
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel

Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this year’s DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement